^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Norepinephrine reuptake inhibitor

    Related drugs:
    4d
    The Current Status of Nuclear Medicine in Africa. (PubMed, J Nucl Med)
    177Lu-therapies are restricted to 7 countries, and the availability of [131I]MIBG remains limited...Sustained investment in facilities, training, and regulatory frameworks is essential to achieve equitable access to care. IAEA's regional anchor centers as part of the Rays of Hope initiative exemplifies strategic capacity building, collaboration, and knowledge sharing in the region.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Azedra (iobenguane I 131)
    6d
    The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=750, Recruiting, Beijing Tiantan Hospital | N=384 --> 750
    Enrollment change
    12d
    NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (clinicaltrials.gov)
    P2, N=118, Not yet recruiting, New Approaches to Neuroblastoma Therapy Consortium
    New P2 trial
    |
    Zolinza (vorinostat) • Unituxin (dinutuximab) • Azedra (iobenguane I 131)
    13d
    Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov)
    P1, N=40, Recruiting, University of Minnesota | Trial completion date: Nov 2029 --> Jul 2027 | Trial primary completion date: Nov 2028 --> Jul 2026
    Trial completion date • Trial primary completion date
    13d
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    13d
    Duloxetine for LBP (clinicaltrials.gov)
    P4, N=120, Recruiting, Montefiore Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    15d
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine
    16d
    A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels (clinicaltrials.gov)
    P1, N=174, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    17d
    CONCORD: Combination of Novel Therapies for CKD Comorbid Depression (clinicaltrials.gov)
    P2, N=201, Recruiting, Stony Brook University | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    25d
    Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans (clinicaltrials.gov)
    P1, N=122, Completed, University of Zurich | Recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    27d
    Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov)
    P3, N=44, Recruiting, Tanta University | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    27d
    The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=384, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
    Enrollment open